Advertisement
Screener

CYPHERPUNK TECHNOLOGIES INC. (CYPH) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

CYPHERPUNK TECHNOLOGIES INC. Comprehensive Income

CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Comprehensive Income of $39.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12

  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $39.39M.
  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$77.16M.
  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $40.21M.
  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$3.33M.
  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $4.85M.
  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$67.78M.
  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$81.44M.
  • CYPHERPUNK TECHNOLOGIES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$54.20M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2026-06-30$39.39M
10-Q · filed 2026-08-12
-$37.76M
10-Q · filed 2026-08-12
$2.45M
derived: sum of 3 quarters · filed 2026-08-12
-$876.00K
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$77.16M
10-Q · filed 2026-05-14
-$36.95M
derived: sum of 2 quarters · filed 2026-05-14
-$40.27M
derived: sum of 3 quarters · filed 2026-05-14
-$56.88M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$40.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$36.89M
derived: sum of 2 quarters · filed 2026-03-16
$20.27M
derived: sum of 3 quarters · filed 2026-08-12
$4.85M
10-K · filed 2026-03-16
2025-09-30-$3.33M
10-Q · filed 2025-11-12
-$19.94M
derived: sum of 2 quarters · filed 2026-08-12
-$35.37M
10-Q · filed 2025-11-12
-$50.92M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$16.61M
10-Q · filed 2026-08-12
-$32.04M
10-Q · filed 2026-08-12
-$47.60M
derived: sum of 3 quarters · filed 2026-08-12
-$65.77M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$15.43M
10-Q · filed 2026-05-14
-$30.98M
derived: sum of 2 quarters · filed 2026-05-14
-$49.16M
derived: sum of 3 quarters · filed 2026-05-14
-$69.16M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$15.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$33.73M
derived: sum of 2 quarters · filed 2026-03-16
-$53.73M
derived: sum of 3 quarters · filed 2026-03-16
-$67.78M
10-K · filed 2026-03-16
2024-09-30-$18.17M
10-Q · filed 2025-11-12
-$38.18M
derived: sum of 2 quarters · filed 2025-11-12
-$52.22M
10-Q · filed 2025-11-12
-$65.34M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$20.00M
10-Q · filed 2025-08-14
-$34.05M
10-Q · filed 2025-08-14
-$47.17M
derived: sum of 3 quarters · filed 2025-08-14
-$60.52M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$14.05M
10-Q · filed 2025-05-13
-$27.16M
derived: sum of 2 quarters · filed 2025-05-13
-$40.52M
derived: sum of 3 quarters · filed 2025-05-13
-$53.85M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$13.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
-$26.47M
derived: sum of 2 quarters · filed 2025-03-26
-$39.80M
derived: sum of 3 quarters · filed 2025-03-26
-$81.44M
10-K · filed 2025-03-26
2023-09-30-$13.35M
10-Q · filed 2024-11-13
-$26.68M
derived: sum of 2 quarters · filed 2024-11-13
-$68.32M
10-Q · filed 2024-11-13
-$80.98M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$13.33M
10-Q · filed 2024-08-12
-$54.97M
10-Q · filed 2024-08-12
-$67.63M
derived: sum of 3 quarters · filed 2024-08-12
-$82.13M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$41.64M
10-Q · filed 2024-05-13
-$54.30M
derived: sum of 2 quarters · filed 2024-05-13
-$68.80M
derived: sum of 3 quarters · filed 2024-05-13
-$85.30M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$12.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
-$27.16M
derived: sum of 2 quarters · filed 2024-03-18
-$43.67M
derived: sum of 3 quarters · filed 2024-03-18
-$54.20M
10-K · filed 2024-03-18
2022-09-30-$14.50M
10-Q · filed 2023-11-13
-$31.00M
derived: sum of 2 quarters · filed 2023-11-13
-$41.54M
10-Q · filed 2023-11-13
-$52.35M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$16.50M
10-Q · filed 2023-08-14
-$27.04M
10-Q · filed 2023-08-14
-$37.85M
derived: sum of 3 quarters · filed 2023-08-14
-$48.78M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$10.53M
10-Q · filed 2023-05-15
-$21.34M
derived: sum of 2 quarters · filed 2023-05-15
-$32.28M
derived: sum of 3 quarters · filed 2023-05-15
-$41.69M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$10.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24
-$21.75M
derived: sum of 2 quarters · filed 2023-03-24
-$31.16M
derived: sum of 3 quarters · filed 2023-03-24
-$40.27M
10-K · filed 2023-03-24
2021-09-30-$10.94M
10-Q · filed 2022-11-14
-$20.35M
derived: sum of 2 quarters · filed 2022-11-14
-$29.47M
10-Q · filed 2022-11-14
-$36.67M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$9.41M
10-Q · filed 2022-08-12
-$18.53M
10-Q · filed 2022-08-12
-$25.73M
derived: sum of 3 quarters · filed 2022-08-12
-$33.00M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$9.12M
10-Q · filed 2022-05-13
-$16.32M
derived: sum of 2 quarters · filed 2022-05-13
-$23.59M
derived: sum of 3 quarters · filed 2022-05-13
-$30.97M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$7.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11
-$14.47M
derived: sum of 2 quarters · filed 2022-03-11
-$21.85M
derived: sum of 3 quarters · filed 2022-03-11
-$28.17M
10-K · filed 2022-03-11
2020-09-30-$7.26M
10-Q · filed 2021-11-12
-$14.65M
derived: sum of 2 quarters · filed 2021-11-12
-$20.97M
10-Q · filed 2021-11-12
-$29.21M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$7.38M
10-Q · filed 2021-08-13
-$13.70M
10-Q · filed 2021-08-13
-$21.95M
derived: sum of 3 quarters · filed 2021-08-13
-$29.88M
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31-$6.32M
10-Q · filed 2021-05-14
-$14.57M
derived: sum of 2 quarters · filed 2021-05-14
-$22.50M
derived: sum of 3 quarters · filed 2021-05-14
-$30.82M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31-$8.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
-$16.18M
derived: sum of 2 quarters · filed 2021-03-12
-$24.50M
derived: sum of 3 quarters · filed 2021-03-12
-$33.13M
10-K · filed 2021-03-12
2019-09-30-$7.93M
10-Q · filed 2020-11-12
-$16.25M
derived: sum of 2 quarters · filed 2020-11-12
-$24.88M
10-Q · filed 2020-11-12
-$23.26M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30-$8.32M
10-Q · filed 2020-08-13
-$16.95M
10-Q · filed 2020-08-13
-$15.33M
derived: sum of 3 quarters · filed 2020-08-13
-$21.78M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31-$8.63M
10-Q · filed 2020-05-14
-$7.00M
derived: sum of 2 quarters · filed 2020-05-14
-$13.46M
derived: sum of 3 quarters · filed 2020-05-14
-$20.68M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$1.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
-$4.83M
derived: sum of 2 quarters · filed 2020-03-16
-$12.06M
derived: sum of 3 quarters · filed 2020-03-16
-$22.57M
10-K · filed 2020-03-16
2018-09-30-$6.45M
10-Q · filed 2019-11-14
-$13.68M
derived: sum of 2 quarters · filed 2019-11-14
-$24.19M
10-Q · filed 2019-11-14
-$30.78M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30-$7.22M
10-Q · filed 2019-08-09
-$17.74M
10-Q · filed 2019-08-09
-$24.33M
derived: sum of 3 quarters · filed 2019-08-09
-$31.74M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31-$10.51M
10-Q · filed 2019-05-15
-$17.10M
derived: sum of 2 quarters · filed 2019-05-15
-$24.52M
derived: sum of 3 quarters · filed 2019-05-15
-$30.99M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$6.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01
-$14.01M
derived: sum of 2 quarters · filed 2019-04-01
-$20.48M
derived: sum of 3 quarters · filed 2019-04-01
-$30.29M
10-K · filed 2019-04-01
2017-09-30-$7.42M
10-Q · filed 2018-11-09
-$13.88M
derived: sum of 2 quarters · filed 2018-11-09
-$23.70M
10-Q · filed 2018-11-09
-$28.97M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30-$6.47M
10-Q · filed 2018-08-08
-$16.28M
10-Q · filed 2018-08-08
-$21.56M
derived: sum of 3 quarters · filed 2018-08-08
-$28.99M
derived: sum of 4 quarters · filed 2018-08-08
2017-03-31-$9.81M
10-Q/A · filed 2018-08-08
-$15.09M
derived: sum of 2 quarters · filed 2018-08-08
-$22.52M
derived: sum of 3 quarters · filed 2018-08-08
-$29.99M
derived: sum of 4 quarters · filed 2018-08-08
2016-12-31-$5.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
-$12.71M
derived: sum of 2 quarters · filed 2018-02-23
-$20.18M
derived: sum of 3 quarters · filed 2018-02-23
-$25.34M
10-K · filed 2018-02-23
2016-09-30-$7.43M
10-Q · filed 2017-11-13
-$14.90M
derived: sum of 2 quarters · filed 2017-11-13
-$20.06M
10-Q · filed 2017-11-13
2016-06-30-$7.47M
10-Q · filed 2017-08-11
-$12.63M
10-Q · filed 2017-08-11
2016-03-31-$5.16M
10-Q · filed 2017-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06